Autologous Anti-BCMA CAR T-cells UF-KURE-BCMA

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous CD4+ and CD8+ T-lymphocytes that have been transduced with a lentiviral vector (LV) encoding for a chimeric antigen receptor (CAR) specific for human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA CAR T-cells UF-KURE-BCMA specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.

**Synonyms:** - Autologous Anti-BCMA CAR T Cells UF-KURE-BCMA - Autologous Anti-BCMA CAR-T Cells UF-KURE-BCMA - Autologous Anti-BCMA CAR-expressing CD4+/CD8+ T-lymphocytes UF-KURE-BCMA - UF-KURE-BCMA